FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W8734653> ?p ?o ?g. }

• W8734653 endingPage "29" @default.
• W8734653 startingPage "216" @default.
• W8734653 abstract "Questionnaires on the quality of life and tolerance of different parts of maintenance treatment were sent to a total of 83 patients with multiple myeloma. All patients were for more than one year on maintenance treatment which involved either interferon alpha monotherapy (I), 3 million u. three times per week till signs of relapse developed or sequence administration of interferon alpha and dexamethazone 40 mg on day 1 to 4, 10 to 13 and 20 to 23 and then after a four-week interval again interferon alpha, again till progression of the disease occurred. The patients evaluated the presence or absence of different undesirable effects of treatment during the first two weeks of treatment and throughout the year and listed their intensity into four categories defined in the questionnaire. The quality of life was evaluated by means of a basic module of the questionnaire of the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30). The results of the questionnaire are to a certain extent surprising as from the patients' answers ensues that this maintenance treatment is associated with more numerous undesirable effects than the physicians realized when in contact with the patient. In this summary we can list only the most frequent effects (deterioration of eyesight, impaired sleep, depressions, irritability and unrest, chill, pain in muscles and joints, general weakness and dyspnoea). From the questionnaires on the quality of life ensues a markedly poorer quality of life of these patients as compared with the healthy population. There are however no basic differences between individual groups. The questionnaires were handed only to patients who had maintenance treatment for more than one year and thus patients were eliminated where maintenance treatment was discontinued because of undesirable effects. To give a general idea of the tolerance of the above maintenance treatment the authors mention that to the date of Aug. 31, 2001 113 patients were randomized into one of the branches of maintenance treatment. Maintenance treatment had to be discontinued in 6% patients (in two instances on account of severe hypothyroidism, in one case on account of hallucinations, in three instances on account of severe mental depression caused by this treatment). Reduction of interferon doses in 20% patients usually because of cytopenia but also on account of psychic problem. To the question what length of prolongation of life compensates the undesirable effects of maintenance treatment the following replies were obtained from patients receiving ID, possibly I: 3 months--47.6 and 38.3%, 6 months--4.3 and 10.6%, 9 months--0 and 4.3%, 12 months--47.6 and 46.8% of the addressed patients. In reply to the question whether the patients would prefer, assuming equal effectiveness, a maintenance monotherapy with interferon alpha or dexamethazone more patients preferred interferon to dexamethasone. For practice ensues from this article informing on undesirable effects of maintenance treatment and the effect of maintenance treatment on the quality of life: 1. the necessity of thorough knowledge of physicians of all possible undesirable effects as only a doctor knowing possible undesirable effects of treatment can recognize them, 2. regular monitoring not only of the activity of the basic disease, but also undesirable effects of maintenance treatment and the influence of treatment on the patients' quality of life, 3. the necessity to assess the quality of life in clinical trials as an important parameter for deciding on the way of treatment." @default.
• W8734653 created "2016-06-24" @default.
• W8734653 creator A5003934490 @default.
• W8734653 creator A5005326615 @default.
• W8734653 creator A5006612295 @default.
• W8734653 creator A5012524477 @default.
• W8734653 creator A5014987293 @default.
• W8734653 creator A5016374975 @default.
• W8734653 creator A5020780800 @default.
• W8734653 creator A5020830445 @default.
• W8734653 creator A5026563725 @default.
• W8734653 creator A5028051663 @default.
• W8734653 creator A5030853986 @default.
• W8734653 creator A5031143792 @default.
• W8734653 creator A5031355400 @default.
• W8734653 creator A5034532580 @default.
• W8734653 creator A5037204849 @default.
• W8734653 creator A5038683514 @default.
• W8734653 creator A5040644955 @default.
• W8734653 creator A5042170629 @default.
• W8734653 creator A5042468594 @default.
• W8734653 creator A5046782027 @default.
• W8734653 creator A5055725895 @default.
• W8734653 creator A5058464853 @default.
• W8734653 creator A5064439570 @default.
• W8734653 creator A5072369748 @default.
• W8734653 creator A5074430321 @default.
• W8734653 creator A5082991348 @default.
• W8734653 creator A5083119634 @default.
• W8734653 creator A5089473871 @default.
• W8734653 date "2002-03-01" @default.
• W8734653 modified "2023-10-18" @default.
• W8734653 title "[Quality of life and tolerance of maintenance therapy in patients with multiple myeloma]." @default.
• W8734653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11968583" @default.
• W8734653 hasPublicationYear "2002" @default.
• W8734653 type Work @default.
• W8734653 sameAs 8734653 @default.
• W8734653 citedByCount "0" @default.
• W8734653 crossrefType "journal-article" @default.
• W8734653 hasAuthorship W8734653A5003934490 @default.
• W8734653 hasAuthorship W8734653A5005326615 @default.
• W8734653 hasAuthorship W8734653A5006612295 @default.
• W8734653 hasAuthorship W8734653A5012524477 @default.
• W8734653 hasAuthorship W8734653A5014987293 @default.
• W8734653 hasAuthorship W8734653A5016374975 @default.
• W8734653 hasAuthorship W8734653A5020780800 @default.
• W8734653 hasAuthorship W8734653A5020830445 @default.
• W8734653 hasAuthorship W8734653A5026563725 @default.
• W8734653 hasAuthorship W8734653A5028051663 @default.
• W8734653 hasAuthorship W8734653A5030853986 @default.
• W8734653 hasAuthorship W8734653A5031143792 @default.
• W8734653 hasAuthorship W8734653A5031355400 @default.
• W8734653 hasAuthorship W8734653A5034532580 @default.
• W8734653 hasAuthorship W8734653A5037204849 @default.
• W8734653 hasAuthorship W8734653A5038683514 @default.
• W8734653 hasAuthorship W8734653A5040644955 @default.
• W8734653 hasAuthorship W8734653A5042170629 @default.
• W8734653 hasAuthorship W8734653A5042468594 @default.
• W8734653 hasAuthorship W8734653A5046782027 @default.
• W8734653 hasAuthorship W8734653A5055725895 @default.
• W8734653 hasAuthorship W8734653A5058464853 @default.
• W8734653 hasAuthorship W8734653A5064439570 @default.
• W8734653 hasAuthorship W8734653A5072369748 @default.
• W8734653 hasAuthorship W8734653A5074430321 @default.
• W8734653 hasAuthorship W8734653A5082991348 @default.
• W8734653 hasAuthorship W8734653A5083119634 @default.
• W8734653 hasAuthorship W8734653A5089473871 @default.
• W8734653 hasConcept C126322002 @default.
• W8734653 hasConcept C141071460 @default.
• W8734653 hasConcept C159110408 @default.
• W8734653 hasConcept C1862650 @default.
• W8734653 hasConcept C2776364478 @default.
• W8734653 hasConcept C2778562196 @default.
• W8734653 hasConcept C2779134260 @default.
• W8734653 hasConcept C2779951463 @default.
• W8734653 hasConcept C2780247198 @default.
• W8734653 hasConcept C2780820931 @default.
• W8734653 hasConcept C71924100 @default.
• W8734653 hasConceptScore W8734653C126322002 @default.
• W8734653 hasConceptScore W8734653C141071460 @default.
• W8734653 hasConceptScore W8734653C159110408 @default.
• W8734653 hasConceptScore W8734653C1862650 @default.
• W8734653 hasConceptScore W8734653C2776364478 @default.
• W8734653 hasConceptScore W8734653C2778562196 @default.
• W8734653 hasConceptScore W8734653C2779134260 @default.
• W8734653 hasConceptScore W8734653C2779951463 @default.
• W8734653 hasConceptScore W8734653C2780247198 @default.
• W8734653 hasConceptScore W8734653C2780820931 @default.
• W8734653 hasConceptScore W8734653C71924100 @default.
• W8734653 hasIssue "3" @default.
• W8734653 hasLocation W87346531 @default.
• W8734653 hasOpenAccess W8734653 @default.
• W8734653 hasPrimaryLocation W87346531 @default.
• W8734653 hasRelatedWork W2094229042 @default.
• W8734653 hasRelatedWork W2171681634 @default.
• W8734653 hasRelatedWork W2216943272 @default.
• W8734653 hasRelatedWork W2345547698 @default.
• W8734653 hasRelatedWork W2573920921 @default.

• next